Can you take AOD-9604 and MOTS-c together?

There is no specific, well-documented interaction rule for combining AOD-9604 and MOTS-c in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, AOD-9604 or MOTS-c?

AOD-9604 is currently investigational (in trials) and MOTS-c is preclinical only. "Better researched" depends on your research goal — review each profile's cited sources.

Metabolic · Comparison

AOD-9604 vs MOTS-c

Q: What is the difference between AOD-9604 and MOTS-c?

AOD-9604: AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. It was developed to replicate the fat-metabolizing activity of hGH without the growth-promoting, insulin-desensitizing, or mitogenic effects of full-length hGH. Research has focused on its ability to stimulate lipolysis and inhibit lipogenesis through a non-GHR-dependent mechanism. MOTS-c: MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA — not the nuclear genome like most peptides. Under metabolic stress it translocates to the cell nucleus and regulates gene expression tied to insulin sensitivity, fat oxidation, and stress resistance. It is one of the most novel and closely watched compounds in longevity and metabolic research — but it remains preclinical, with no completed human trials of the native peptide. Both are in the Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

A neutral, side-by-side comparison of two metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

AOD-9604

Investigational (in trials)

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH), specifically amino acids 176–191. It was developed to replicate the fat-metabolizing activity of hGH without the growth-promoting, insulin-desensitizing, or mitogenic effects of full-length hGH. Research has focused on its ability to stimulate lipolysis and inhibit lipogenesis through a non-GHR-dependent mechanism.

Full profile

MOTS-c

Preclinical only

MOTS-c is a 16-amino-acid mitochondria-derived peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA — not the nuclear genome like most peptides. Under metabolic stress it translocates to the cell nucleus and regulates gene expression tied to insulin sensitivity, fat oxidation, and stress resistance. It is one of the most novel and closely watched compounds in longevity and metabolic research — but it remains preclinical, with no completed human trials of the native peptide.

Full profile

	AOD-9604	MOTS-c
Category	Metabolic	Metabolic
Also known as	Anti-Obesity Drug 9604, hGH Fragment 176-191, Tyr-hGH Frag 176-191	Mitochondrial Open Reading Frame of the 12S rRNA type-c, MOTS-c peptide, mitochondrial-derived peptide
Evidence	Investigational (in trials)	Preclinical only
Dosing range	250mcg–1000mcg mcg, Once daily, on an empty stomach	5mg–20mg mg, varies widely (research protocols are extrapolated from rodent data; no validated human regimen exists)
Administration	Subcutaneous injection, Oral (significantly reduced bioavailability)	Subcutaneous injection, Intravenous (research settings)
Key side effects	Injection site redness or irritation, Mild flushing (transient), Headache (rare), Considered low side-effect profile compared to full hGH	Generally well-tolerated in animal studies, Injection site reactions, Theoretical hypoglycemia risk in diabetics or those on insulin sensitizers (AMPK activation), Human safety data are essentially absent — this is an early-stage research compound
Cited sources	3 references	6 references

Key differences

Evidence level differs: AOD-9604 is investigational (in trials), while MOTS-c is preclinical only.
Administration: AOD-9604 — Subcutaneous injection, Oral (significantly reduced bioavailability); MOTS-c — Subcutaneous injection, Intravenous (research settings).
Dosing units differ: AOD-9604 is dosed in mcg, MOTS-c in mg — they operate at different scales.
Frequency: AOD-9604 is typically Once daily, on an empty stomach; MOTS-c is varies widely (research protocols are extrapolated from rodent data; no validated human regimen exists).
Research depth: this profile cites 3 sources for AOD-9604 vs 6 for MOTS-c.

How each works

AOD-9604

Animal studies consistently demonstrate that AOD-9604 reduces body fat in obese rodents without affecting blood glucose or IGF-1 levels — a significant distinction from hGH. It appears to act directly on fat cells via beta-adrenergic pathways. Phase 2 human clinical trials for obesity were conducted but did not meet primary endpoints for the oral formulation; injectable forms were not advanced to Phase 3. AOD-9604 received GRAS (Generally Recognized As Safe) status in the US for food use, though this does not confer therapeutic approval.

MOTS-c

MOTS-c activates AMPK via the folate–methionine–AICAR pathway and, under metabolic stress, moves into the nucleus to coordinate antioxidant and stress-response gene programs (partly via Nrf2/ARE). In rodent and cell models it reverses high-fat-diet insulin resistance, reduces obesity, and — when injected into aged mice — substantially improves treadmill running capacity, behaving like an 'exercise mimetic.' In humans, exercise raises endogenous MOTS-c, and an East-Asian genetic variant (K14Q) shows mixed associations with longevity and with type 2 diabetes risk. No registered human clinical trials of MOTS-c itself exist; the only human study was of an analog (CB4211), a Phase 1 program that was discontinued.

Read the full AOD-9604 profile Read the full MOTS-c profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.